RMD RESMED INC

CIK 0000943819 42 ready 8-Ks latest August 6, 2026, 4:05 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (4)

Ready 8-Ks 42

Latest filing August 17, 2026, 4:30 PM ET

Top materiality 0.85

Event mix earnings ×21 · leadership ×10 · other ×4

Sentiment 23 pos · 0 neg · 19 neu

Latest earnings reported 2026-Q3

Executive change recent →

Recent 8-K filings for RMD

Highest-materiality recent filing

ResMed Q1 FY2025 revenue $1.22B (+11% YoY); EPS $2.11; non-GAAP EPS $2.20; dividend $0.53

October 24, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 8.01 item 9.01

Revenue $1,224.5M, up 11% YoY (11% constant currency), driven by sleep device and mask demand.
GAAP diluted EPS $2.11; non-GAAP diluted EPS $2.20, up 34% YoY; operating profit up 34%.

Read filing →

August 6, 2026, 4:05 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

ResMed Q4 revenue up 9% to $1.5B; non-GAAP EPS $2.95 (+16%); dividend raised 10%

Q4 revenue $1.464B (+9% YoY); GAAP EPS $2.64 (+2%); non-GAAP EPS $2.95 (+16%).
July 7, 2026, 5:24 PM ET M&A materiality 0.75 positive item 2.02 item 7.01 item 9.01

ResMed sells MatrixCare to Frazier Healthcare for $490M cash; sharpens focus on sleep health

All-cash deal valued at $490M, subject to closing adjustments; expected to close in Q1 FY2027.
April 30, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

ResMed Q3 revenue $1.43B (+11%); GAAP EPS $2.74, dividend $0.60

Revenue $1,431.4M (+11% reported, +8% constant currency).
April 30, 2026, 7:59 PM ET leadership materiality 0.70 neutral item 5.02 item 9.01 ◈ executive_change ×2

ResMed CFO Brett Sandercock retires; Aaron Bloomer appointed successor

Brett Sandercock retires as CFO effective May 4, 2026; remains special advisor to CEO through Dec 2027.
January 29, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

ResMed Q2 FY2026: Revenue $1.42B (+11% YoY), non-GAAP EPS $2.81, dividend $0.60

Revenue $1,422.8M, up 11% YoY (9% constant currency); gross margin expanded 320 bps to 61.8%.
October 30, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

ResMed Q1 FY2026 revenue +9% to $1.34B; non-GAAP EPS $2.55 (+16%); dividend $0.60

Revenue $1,335.6M (+9% YoY, +8% constant currency); diluted EPS $2.37, non-GAAP EPS $2.55 (+16%).
July 31, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 8.01 item 9.01

ResMed Q4 revenue up 10% to $1.35B, EPS $2.58; dividend raised 13% to $0.60

Q4 revenue $1.35B (+10% YoY, +9% CC); GAAP EPS $2.58 (+30%), non-GAAP EPS $2.55 (+23%).
April 23, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

ResMed Q3 FY2025: revenue $1.29B (+8%), GAAP EPS $2.48 (+22%), non-GAAP EPS $2.37 (+11%)

Revenue of $1.29B (+8% YoY; +9% constant currency); GAAP diluted EPS $2.48 vs $2.04 (+22%).
January 30, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

ResMed reports Q2 FY2025 revenue up 10% to $1.28B; non-GAAP EPS $2.43, up 29%

Revenue $1.28B (+10% YoY); gross margin 58.6% (+300 bps) on manufacturing efficiencies.
October 24, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 8.01 item 9.01

ResMed Q1 FY2025 revenue $1.22B (+11% YoY); EPS $2.11; non-GAAP EPS $2.20; dividend $0.53

Revenue $1,224.5M, up 11% YoY (11% constant currency), driven by sleep device and mask demand.
August 1, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 8.01 item 9.01

ResMed Q4 revenue $1.22B (+9% YoY); EPS $1.98; dividend up 10% to $0.53

Q4 FY2024 revenue $1,223.2M (+9% YoY, +10% constant currency); gross margin 58.5% (+350 bps).
April 25, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

ResMed Q3 FY2024 revenue $1.20B, +7% YoY; GAAP EPS $2.04, non-GAAP $2.13

Revenue $1.197B up 7% YoY (7% constant currency); mask/accessories double-digit growth.
January 24, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

ResMed Q2 FY2024 revenue $1.16B (+12% YoY); non-GAAP EPS $1.88 (+13%)

Revenue $1,162.8M (+12% YoY, +11% constant currency); GAAP op profit down 2%, non-GAAP op profit up 20% to $365.5M.
November 9, 2023, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01 ◈ executive_change ×3

ResMed appoints new CPO, CMO, CRO; COO Douglas to retire Jan 1, 2024

Rob Douglas, President & COO, retires Jan 1, 2024; transitions to special advisor to CEO immediately.
October 26, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

ResMed Q1 FY2024 revenue up 16% to $1.10B; non-GAAP EPS $1.64 (+9% YoY)

Revenue $1,102.3M (+16% YoY); operating income $289.0M (+5%); non-GAAP operating profit +10%.
August 3, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases ×2

ResMed Q4 FY2023 revenue up 23% to $1.12B; EPS $1.56 GAAP, dividend raised 9% to $0.48

Revenue $1,122.1M +23% YoY; GAAP diluted EPS $1.56 (+17%), non-GAAP $1.60 (+7%).
April 27, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

ResMed Q3 FY2023 revenue +29% to $1.12B; EPS $1.58, non-GAAP $1.68

Revenue $1,116.9M, up 29% YoY (31% constant currency); diluted EPS $1.58, non-GAAP $1.68.
January 26, 2023, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 5.02 item 8.01 item 9.01 ◈ executive_change ×2◈ Earnings Releases

ResMed Q2 revenue up 16% to $1.03B, EPS $1.53; CEO Farrell appointed Board Chair

Revenue $1,033.7M (+16% YoY, +20% constant currency); GAAP EPS $1.53, non-GAAP $1.66.
October 27, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

ResMed Q1 FY23 revenue $950.3M (+5% YoY, +9% CC); GAAP EPS $1.43, non-GAAP $1.51

Revenue $950.3M, up 5% YoY (9% constant currency); Americas (ex-SaaS) revenue up 18%.
August 12, 2022, 7:59 PM ET M&A materiality 0.75 neutral item 8.01 item 1.01 item 7.01 item 9.01

ResMed to acquire MediFox-Dan for EUR 810M; closing expected by Dec 31, 2022

Base purchase price of EUR 810M fixed via locked box; enterprise value EUR 950M.
August 11, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

ResMed Q4 revenue $914.7M (+4% YoY); dividend up 5% to $0.44; acquires MEDIFOX DAN for $1B

Q4 revenue $914.7M (+4% YoY, +8% constant currency); GAAP diluted EPS $1.33.
June 14, 2022, 7:59 PM ET M&A materiality 0.85 positive item 1.01 item 7.01 item 9.01

ResMed to acquire German out-of-hospital software leader MEDIFOX DAN for ~$1B

Purchase price ~US$1.0B (€950M); expected to close by Dec 31, 2022 subject to German regulatory clearances.
April 28, 2022, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 8.01 item 9.01

ResMed Q3 revenue up 12% to $864.5M; non-GAAP EPS $1.32, up 2% YoY

Revenue $864.5M (+12% YoY); constant currency growth 14%.
January 27, 2022, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 8.01 item 9.01

ResMed Q2 FY2022: Revenue $894.9M (+12% YoY), GAAP EPS $1.37, non-GAAP $1.47; dividend $0.42

Revenue $894.9M, up 12% YoY (13% constant currency); operating income $248.7M, up 12%.
October 28, 2021, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 8.01 item 9.01

ResMed reports Q1 FY2022 revenue $904M (+20% YoY), diluted EPS $1.39, non-GAAP EPS $1.51

Revenue $904.0M, up 20% YoY (19% constant currency); all segments grew double-digits.
August 5, 2021, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 8.01 item 9.01

ResMed Q4 FY2021 revenue up 14% to $876.1M, dividend increased 8% to $0.42

Q4 revenue $876.1M (+14% YoY); non-GAAP operating profit up 7%; diluted non-GAAP EPS $1.35.

Executive changes

Appointed

Carol Burt

Lead Director

RMD · RESMED INC

Effective: 2026-11-15
Filed: August 17, 2026, 4:30 PM ET

the Board approved the appointment of Carol Burt as lead director, effective November 15, 2026.

Departed

Ronald Taylor

Director

RMD · RESMED INC

Effective: 2026-11-18
Filed: August 17, 2026, 4:30 PM ET

On August 13, 2026, Ronald Taylor, a director of Resmed, informed the Board that he will not stand for election at Resmed’s 2026 annual meeting of stockholders (the “Annual Meeting”) and intends to retire from the Board, effective at the Annual Meeting, which is expected to be held on November 18, 2026.

Appointed

Aaron Bloomer

Chief Financial Officer

RMD · RESMED INC

Effective: 2026-05-04
Filed: April 30, 2026, 7:59 PM ET

On April 30, 2026, the Company also announced it appointed Aaron Bloomer, age 40, as Chief Financial Officer, effective May 4, 2026.

Departed

Brett Sandercock

Chief Financial Officer

RMD · RESMED INC

Effective: 2026-05-04
Successor: Aaron Bloomer
Filed: April 30, 2026, 7:59 PM ET

On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.

Appointed

Christopher DelOrefice

Director

RMD · RESMED INC

Effective: 2024-08-15
Filed: August 16, 2024, 7:59 PM ET

On August 15, 2024, ResMed Inc. appointed Christopher DelOrefice to serve on its board of directors, with a term expiring at ResMed’s 2024 annual meeting of stockholders on November 21, 2024

Departed

Robert Douglas

special advisor to the CEO

RMD · RESMED INC

Effective: 2024-01-01
Filed: November 9, 2023, 6:59 PM ET

On November 9, 2023, we announced that Robert Douglas, our chief operating officer and president, will transition to a role as special advisor to the CEO effective immediately and will retire, effective January 1, 2024.

Role change

Robert Douglas

special advisor to the CEO

RMD · RESMED INC

Effective: 2023-11-09
Filed: November 9, 2023, 6:59 PM ET

On November 9, 2023, we announced that Robert Douglas, our chief operating officer and president, will transition to a role as special advisor to the CEO effective immediately and will retire, effective January 1, 2024.

Role change

Lucile Blaise

senior vice president, strategy & business development

RMD · RESMED INC

Effective: 2023-11-09
Filed: November 9, 2023, 6:59 PM ET

Lucile Blaise, our former president, sleep & respiratory care, will transition to a role as senior vice president, strategy & business development, reporting to our Chief Strategy Officer.

Departed

David Pendarvis

global general counsel, chief administrative officer, and secretary

RMD · RESMED INC

Effective: 2023-06-30
Filed: March 30, 2023, 7:59 PM ET

On March 29, 2023, David Pendarvis, our global general counsel, chief administrative officer, and secretary, notified us that he intends to retire, effective June 30, 2023.

Appointed

Michael J. 'Mick' Farrell

chair of the board of directors

RMD · RESMED INC

Effective: 2023-01-25
Filed: January 26, 2023, 6:59 PM ET

On January 25, 2023, our board of directors appointed Michael J. “Mick” Farrell as chair of our board of directors.

Role change

Dr. Peter C. Farrell

chair emeritus

RMD · RESMED INC

Effective: 2023-01-25
Filed: January 26, 2023, 6:59 PM ET

In recognition of Dr. Farrell’s long and valuable service as chair, the board of directors appointed him to the new director position of chair emeritus, effective immediately.

Role change (interim)

Robert Douglas

Interim President, Sleep and Respiratory Care

RMD · RESMED INC

Effective: 2022-07-01
Successor: Lucile Blaise
Filed: July 1, 2022, 7:59 PM ET

Concurrent with Ms. Blaise’s July 1, 2022 appointment, Robert Douglas will no longer serve as our interim president, sleep and respiratory care business.

Earnings & guidance

2026-Q3 EPS reported $7.79 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event earnings

23 positive 0 negative 19 neutral

source · RMD on sec.gov